ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Osteoporosis
Conditions
Primary Osteoporosis
Trial Timeline
Mar 1, 2007 → Dec 1, 2011
NCT ID
NCT00447915About ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS is a phase 3 stage product being developed by Chugai Pharmaceutical for Primary Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00447915. Target conditions include Primary Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00447915 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Osteoporosis